Enter Italy
The Italian market is complex. We navigate it together, without getting lost.
Market entry →Science gets you in the room.
Trust closes the deal.
Let's build it.
Why deals fail
Brilliant science is necessary.
It is not sufficient.
Investors fund theses, not data. Partners commit to people, not products. Institutions move for relationships, not proposals. For 20 years I've worked at the intersection where science becomes a decision - across Europe, Asia, and the US.
0+
Years in life sciences
0
Languages spoken fluently
0
Joint labs built across 3 continents
Three ways I work with you
Science. Stories. Trust.
Build your venture
Your science is the asset. I build the story that makes it fundable.
Venture building →Build partnerships
Complex cross-border deals need a bridge. I've been building them for 20 years.
Partnerships →Who I am
I am not a scientist. That's why I ask the questions that matter.
When a researcher presents a discovery, my first question is always the same: so what? Not because the answer is obvious - but because often it isn't yet. That question, asked with curiosity and respect, is where every path to market begins. For 20 years I've built bridges. Between research and capital. Between Italy and the world. Between a discovery and its market.
Latest Insights
At the intersection of science, stories, and trust - insights for life sciences companies building across borders.
Featured
Published on April 9, 2026
Reading time: 8 min read
You have a patent. Now what?
Most patented inventions are never commercialised. The patent is the beginning of the journey, not the destination. Here is the roadmap.
technology transfer
spinout
licensing
Published on April 14, 2026Reading time: 7 min
The ask is not a budget. It's a value proposition.
A funding request framed as a budget requires the investor to do additional work. A funding request framed as a value proposition does that work for them.
fundraising
investor readiness
Published on March 30, 2026Reading time: 10 min
Five conditions a pharma company needs before it buys
Understanding the real buyer — and building your equity story around their decision criteria — is the most important repositioning a founder can make.
equity story
fundraising
Worth reading. Worth keeping.
Strategic notes on biotech fundraising and venture design. When there is something worth saying. Unsubscribe anytime.
The gap between your science and its market won't close itself.
30 minutes. No pitch. Just an honest conversation.
Book a 30-Minute Call